Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 21Neurofibromatosis 1 19Neurofibroma, Plexiform 11Melanoma 11Lung Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Breast Neoplasms 7Solid Tumours 5Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Rectal Neoplasms 3Neurofibrosarcoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Renal Insufficiency 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × AZD 6244 × Clear all
NCT00553332 2016-04-22

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled 11 charts
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT01029418 2015-04-16

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

National Cancer Centre, Singapore

Phase 1/2 Terminated
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00604721 2014-05-28

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 8 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡